Women’s health company Hologic Inc. (NSDQ:HOLX) touted promising results from its 6-year targeted breast cancer therapy study using its MammoSite radiation system.
The Bedford, Mass.-based company boasted 90.4 percent "excellent/good" cosmetic results for the more than 1,400 patients who underwent the procedure, according to a press release.
MammoSite, which first won FDA clearance in 2002, allows radiation oncologists to target radiation and adjust the dose to deliver the therapy directly where cancer is most likely to recur.
"This targeting helps minimize side effects such as skin discoloration and scarring, burning, fatigue, and damage to surrounding organs," according to the release
The registry, conducted with the American Society of Breast Surgeons, is the only 6-year follow-up data available for breast brachytherapy balloon systems, the company wrote.
That’s more good news for Hologic, which won FDA clearance for the nation’s first 3D digital mammography system, Selenia Dimensions, in February 2011.